353 related articles for article (PubMed ID: 21884870)
1. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Hochholzer W; Trenk D; Mega JL; Morath T; Stratz C; Valina CM; O'Donoghue ML; Bernlochner I; Contant CF; Guo J; Sabatine MS; Schömig A; Neumann FJ; Kastrati A; Wiviott SD; Sibbing D
Am Heart J; 2011 Sep; 162(3):518-26.e5. PubMed ID: 21884870
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
3. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
6. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Zhu B; Effron MB; Kulkarni MP; Li YG; Jakubowski JA; Miller DL; Baker BA; Luo J; Small DS; Winters KJ
J Cardiovasc Pharmacol; 2011 Mar; 57(3):317-24. PubMed ID: 21266916
[TBL] [Abstract][Full Text] [Related]
7. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
[TBL] [Abstract][Full Text] [Related]
8. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Alexopoulos D; Xanthopoulou I; Davlouros P; Plakomyti TE; Panagiotou A; Mavronasiou E; Hahalis G
Am Heart J; 2011 Oct; 162(4):733-9. PubMed ID: 21982667
[TBL] [Abstract][Full Text] [Related]
15. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
17. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
Cornel JH; Ohman EM; Neely B; Clemmensen P; Sritara P; Zamoryakhin D; Armstrong PW; Prabhakaran D; White HD; Fox KA; Gurbel PA; Roe MT;
Am Heart J; 2014 Jul; 168(1):76-87.e1. PubMed ID: 24952863
[TBL] [Abstract][Full Text] [Related]
18. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
[TBL] [Abstract][Full Text] [Related]
19. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schömig A; Kastrati A; Sibbing D
Platelets; 2013; 24(1):15-25. PubMed ID: 22372531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
